Graves' ophthalmopathy.
Bahn RS.
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
Treatment of Graves' ophthalmopathy.
González-García A, Sales-Sanz M.
Med Clin (Barc). 2021 Feb 26;156(4):180-186. doi: 10.1016/j.medcli.2020.07.031. Epub 2020 Oct 14.
2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.
Hoang TD, Stocker DJ, Chou EL, Burch HB.
Endocrinol Metab Clin North Am. 2022 Jun;51(2):287-304. doi: 10.1016/j.ecl.2021.12.004. Epub 2022 May 11.
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.
Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C, Centanni M, Shoenfeld Y, Ferrari SM.
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101388. doi: 10.1016/j.beem.2020.101388. Epub 2020 Feb 4.
The risk factors for Graves' ophthalmopathy.
Cao J, Su Y, Chen Z, Ma C, Xiong W.
Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1043-1054. doi: 10.1007/s00417-021-05456-x. Epub 2021 Nov 17.
Euthyroid Graves' ophthalmopathy.
Schattner A, Voichanski S, Pollack R, Uliel L.
QJM. 2023 Nov 24;116(11):942-943. doi: 10.1093/qjmed/hcad176.
Management of Graves' ophthalmopathy by radiotherapy: A literature review.
Beige A, Boustani J, Bouillet B, Truc G.
Cancer Radiother. 2024 Jun;28(3):282-289. doi: 10.1016/j.canrad.2023.09.004. Epub 2024 Jun 20.
Immunotherapy for Graves' ophthalmopathy.
Salvi M.
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097.
Practical Guidelines Management of Graves Ophthalmopathy.
Subekti I, Soewondo P, Soebardi S, Darmowidjojo B, Harbuwono DS, Purnamasari D, Tarigan TJE, Wisnu W, Tahapary DL, Kurniawan F, Sidik M, Nusanti S, Dewiputri S, Suharko H, Suardana GG, Suroyo I, Wulani V, Siswoyo AD, Gondhowiardjo S, Kodrat H.
Acta Med Indones. 2019 Oct;51(4):364-371.
Advances of IGF-1R inhibitors in Graves' ophthalmopathy.
Wang M, Liu L.
Int Ophthalmol. 2024 Nov 22;44(1):435. doi: 10.1007/s10792-024-03358-5.
